Sodium N-(8-[2-hydroxybenzoyl] amino) Caprylate (SNAC)[1]
Permeation Enhancer to enable Oral administration
SNAC causes a local increase of pH leading to higher solubility and protection from proteolytic degradation.
Approximately 1% of Semaglutide is absorbed, the rest is degraded in the GI tract.
Structural modifications prevent degradation by DPP-4 and prolong Incretin activity[2] [3]
GLP-1 RAs Target 6 of the 8 Pathophysiologic Defects in the Ominous Octet [6]
Glucose-Dependent Mechanism of Action [4]
Semaglutide improves the efficiency of incretin function by activating GLP-1 receptors.
It acts by numerous mechanisms like
It acts by numerous mechanisms like
Thereby reducing both fasting as well as post - prandial glucose
Healthy Lifestyle Behaviors; Diabetes Self-Management Education and Support (DSMES); Social Determinants of Health (SDOH)
Approved for cardiovascular benefits along with other metabolic disorders
Now approved by FDA* & EMA** for CV risk reduction in
T2DM based on SOUL trial results
Early or Recently Diagnosed T2DM Patient
Established T2DM Patient
Needle Naive or Needle Phobic Patients
Advanced T2DM Patient
Hierarchies of Preferred Medications for Complication Centric Care of People with ABCD
Take Sem-O in the morning
Patients must take Sem-O on an empty stomach.
Take with half a glass of water (equivalent to 120ml)
Do not take Sem-O with any other liquids besides water.
Wait 30 minutes before the first food, beverage, or other oral medications of the day
Waiting less than 30 minutes or taking with food, beverages (other than plain water), or other oral medications will lessen the effect of Sem-O by decreasing absorption. Waiting more than 30 minutes to eat may increase the absorption of Sem-O.
Swallow tablet whole
Do not split, crush, or chew. Do not take more than 1 tablet per day.
Dosing Schedule [16]
[1] SNAC - Sodium N-(8-[2-hydroxybenzoyl] amino) Caprylate
[2] SNAC - Sodium N-(8-[2-hydroxybenzoyl] amino) Caprylate Ref: Diabetes Obes Metab. 2020;22:1263–1277
[3] Kalra, Sanjay & Das, Sambit & Zargar, Abdul. (2022). A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form. Indian Journal of Endocrinology and Metabolism. 26. 98.
[4] Rev Endocr Metab Disord. 2022 Jan 7;23(3):521–539
[5] https://myendoconsult.com/learn/the-ominous-octet-of-t2dm-m-o-a/#t-1760594955866,
[6] Arragan Lezama CA, Jaramillo Ramos JJ, Armas Eguizábal DA, Solares Ovando XS, Minera Villagrán JC, Males Caiza CJ. Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Interlinked Pathophysiology and Integrated Management Approach. Cureus. 2025 Jun 11;17(6):e85813. doi: 10.7759/cureus.85813. PMID: 40662045; PMCID: PMC12257864.
[7] Diabetes Care 2025;48(Suppl. 1): S181–S206
[8] Nadolsky, Karl et al. Endocrine Practice, Volume 31, Issue 11, 1351 – 1394
[9] Rebelo, T. G., de Araujo Paysano, M. L. B., Matheus, G. T. F. U., Ribeiro, D. M., Said, T. B., & Kelly, F. A. (2025). Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis. International Journal of Cardiology, 440, 133683.
[10] Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK,Christiansen E, Hertz CL, Haluzík M. PIONEER 1: randomized clinical trial of the efficacy and safety oforal semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes care. 2019 Sep 1;42(9):1724-32
[11] Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M, PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. Jama. 2019 Apr 16;321(15):1466-80.
[12] Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes care. 2019 Dec 1;42(12):2272-81.
[13] Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes care. 2019 Dec 1;42(12):2262-71.
[14] Bain SC, Mosenzon O, Arechavaleta R, Bogdański P, Comlekci A, Consoli A, Deerochanawong C, Dungan K, Faingold MC, Farkouh ME, Franco DR. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes, Obesity and Metabolism. 2019 Mar;21(3):499-508.
[15] https://getzpharma.com/wp-content/uploads/2025/09/Sem-O-Leaflet-Folded.pdf
[16] https://getzpharma.com/wp-content/uploads/2025/09/Sem-O-Leaflet-Folded.pdf
[17] McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB; SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England Journal of Medicine. 2025;392(20):2001–2012. https://doi.org/10.1056/NEJMoa2501006
[18] Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019 Dec 1;42(12):2272–2281
[19] Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M; PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019 Apr 16;321(15):1466–1480
Abbreviations: